CA3163498A1 - Methods for the detection and treatment of lung cancer - Google Patents
Methods for the detection and treatment of lung cancerInfo
- Publication number
- CA3163498A1 CA3163498A1 CA3163498A CA3163498A CA3163498A1 CA 3163498 A1 CA3163498 A1 CA 3163498A1 CA 3163498 A CA3163498 A CA 3163498A CA 3163498 A CA3163498 A CA 3163498A CA 3163498 A1 CA3163498 A1 CA 3163498A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- biological sample
- lung cancer
- sftpb
- cea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063086865P | 2020-10-02 | 2020-10-02 | |
| US63/086,865 | 2020-10-02 | ||
| US202063106187P | 2020-10-27 | 2020-10-27 | |
| US63/106,187 | 2020-10-27 | ||
| PCT/US2021/052611 WO2022072471A1 (en) | 2020-10-02 | 2021-09-29 | Methods for the detection and treatment of lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3163498A1 true CA3163498A1 (en) | 2022-04-07 |
Family
ID=80950972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3163498A Pending CA3163498A1 (en) | 2020-10-02 | 2021-09-29 | Methods for the detection and treatment of lung cancer |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240159753A1 (https=) |
| EP (1) | EP4222287A4 (https=) |
| JP (1) | JP2023545017A (https=) |
| KR (1) | KR20230080442A (https=) |
| CA (1) | CA3163498A1 (https=) |
| WO (1) | WO2022072471A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110291397A (zh) * | 2017-02-09 | 2019-09-27 | 得克萨斯大学体系董事会 | 肺癌的检测和治疗方法 |
| CA3165068A1 (en) | 2020-01-30 | 2021-08-05 | John E. Blume | Lung biomarkers and methods of use thereof |
| US12334190B2 (en) | 2021-03-31 | 2025-06-17 | PrognomIQ, Inc. | Multi-omic assessment using proteins and nucleic acids |
| GB2607436A (en) * | 2021-03-31 | 2022-12-07 | Prognomiq Inc | Multi-omic assessment |
| US12387508B2 (en) | 2021-09-10 | 2025-08-12 | PrognomIQ, Inc. | Direct classification of raw biomolecule measurement data |
| US12007397B2 (en) | 2021-09-13 | 2024-06-11 | PrognomIQ, Inc. | Enhanced detection and quantitation of biomolecules |
| WO2024107923A1 (en) * | 2022-11-17 | 2024-05-23 | Board Of Regents, The University Of Texas System | Methods for the detection and treatment of lung cancer |
| EP4721103A2 (en) * | 2023-05-31 | 2026-04-08 | Board of Regents, The University of Texas System | Methods for the detection and treatment of lung cancer |
| GB202310137D0 (en) * | 2023-07-03 | 2023-08-16 | Belgian Volition Srl | Method for the detection of cancer |
| WO2025064345A2 (en) * | 2023-09-22 | 2025-03-27 | Board Of Regents, The University Of Texas System | Methods for the detection and treatment of lung cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1610127B1 (en) * | 2003-03-11 | 2012-04-25 | CRC Inc. | N1,n12-diacetylspermine as tumor marker |
| CN102943108B (zh) * | 2006-01-05 | 2014-05-21 | 俄亥俄州立大学研究基金会 | 用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物 |
| WO2012006632A2 (en) * | 2010-07-09 | 2012-01-12 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| WO2013154998A1 (en) * | 2012-04-09 | 2013-10-17 | Duke University | Serum biomarkers and pulmonary nodule size for the early detection of lung cancer |
| US9753037B2 (en) * | 2013-03-15 | 2017-09-05 | Rush University Medical Center | Biomarker panel for detecting lung cancer |
| CA3198282A1 (en) * | 2015-06-26 | 2016-12-29 | Biomark Cancer Systems Inc. | Method of detecting lung cancer |
| CN109478231A (zh) * | 2016-04-01 | 2019-03-15 | 20/20基因系统股份有限公司 | 帮助区别良性和恶性放射线照相明显肺结节的方法和组合物 |
| EP3361256A1 (en) * | 2017-02-08 | 2018-08-15 | Fundación para la Investigación Médica Aplicada | In vitro method for the diagnosis of lung cancer |
| CN110291397A (zh) * | 2017-02-09 | 2019-09-27 | 得克萨斯大学体系董事会 | 肺癌的检测和治疗方法 |
-
2021
- 2021-09-29 KR KR1020237014384A patent/KR20230080442A/ko active Pending
- 2021-09-29 JP JP2023520341A patent/JP2023545017A/ja active Pending
- 2021-09-29 EP EP21876378.7A patent/EP4222287A4/en active Pending
- 2021-09-29 CA CA3163498A patent/CA3163498A1/en active Pending
- 2021-09-29 WO PCT/US2021/052611 patent/WO2022072471A1/en not_active Ceased
-
2023
- 2023-03-31 US US18/193,917 patent/US20240159753A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022072471A1 (en) | 2022-04-07 |
| EP4222287A4 (en) | 2024-12-18 |
| US20240159753A1 (en) | 2024-05-16 |
| EP4222287A1 (en) | 2023-08-09 |
| KR20230080442A (ko) | 2023-06-07 |
| JP2023545017A (ja) | 2023-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240159753A1 (en) | Methods for the detection and treatment of lung cancer | |
| US12405274B2 (en) | Methods for the detection and treatment of lung cancer | |
| US20230393150A1 (en) | Methods and algorithms for aiding in the detection of cancer | |
| US11193935B2 (en) | Compositions, methods and kits for diagnosis of lung cancer | |
| Roe et al. | Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study | |
| WO2016094330A2 (en) | Methods and machine learning systems for predicting the liklihood or risk of having cancer | |
| EP3698144B1 (en) | Compositions, methods and kits for diagnosis of lung cancer | |
| WO2024107923A1 (en) | Methods for the detection and treatment of lung cancer | |
| US20240044902A1 (en) | Methods for the detection and treatment of ovarian cancer | |
| Hyon et al. | Extracellular Vesicle Proteome Analysis Improves Diagnosis of Recurrence in Triple‐Negative Breast Cancer | |
| WO2015042454A1 (en) | Compositions, methods and kits for diagnosis of lung cancer | |
| JP2019502916A (ja) | マーカー、ヒト精巣上体タンパク質４（ｈｅ４）に基づく肺腺癌の再発を検出する方法および関連する使用 | |
| Li et al. | Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study | |
| JP2024540836A (ja) | 肺癌の予測及びその利用 | |
| CN116529603A (zh) | 用于检测和治疗肺癌的方法 | |
| HK40105704A (zh) | 肺癌的检测和治疗方法 | |
| Zhu et al. | Profiles of blood biomarkers in lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220531 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240809 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240920 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240920 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240920 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250205 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250218 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250218 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250918 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250919 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250919 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260112 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260127 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260127 |